Latest Strategy News

MaxiPARTS Limited reported a robust FY25 with a 57% jump in net profit and a 20% dividend increase, underpinned by operational gains and a key acquisition in Förch Australia.

London City Equities reported a $11.3 million capital gain primarily from trimming its Fiducian Group stake, reversing prior losses to post a $500,000 profit and declaring a 2.5 cent fully franked dividend including a special payout.

Australian Vintage Limited reported a strong FY25 with significant profit growth despite flat revenue, underpinned by innovation and cost-cutting initiatives. The company aims for positive free cash flow in FY26, propelled by global brand expansion and operational efficiencies.

Australian Vintage Ltd reported a modest 1% revenue decline in FY25 but significantly narrowed its net loss, setting the stage for a transformational FY26 driven by new CEO leadership and innovative product launches.

Cadence Opportunities Fund Limited reported a solid 7.9% gain for the 2025 financial year, driven by strong gold mining stocks and strategic portfolio moves. The fund also declared a fully franked final dividend of 7.0 cents per share, reflecting confidence despite ongoing economic uncertainties.

Cadence Opportunities Fund Limited reported a 36% drop in profit after tax for FY2025 but maintained its fully franked final dividend at 7.0 cents per share, signaling confidence despite softer earnings.

Cadence Capital Limited reported a $6.3 million profit and a 3.4% fund gain for FY25, driven by strong gold sector performance. The company announced a 3.0 cent final dividend with a dividend reinvestment plan and on-market buy-back.

Aerometrex has confirmed Robert Veitch as its new CEO and Managing Director, following a strategic overhaul that delivered $2 million in annual cost savings and boosted its MetroMap revenue stream.

Desane Group Holdings anticipates a strong leap in earnings before interest and tax for FY25, nearly doubling last year’s figure. The final audited results are expected by the end of August.

Healius Limited reported a 5.7% rise in FY25 revenue driven by pathology growth, while underlying EBIT fell 27% impacted by cyclone disruptions and restructuring. The company advances its pathology strategy and cost savings post-Lumus divestment.

Healius reported a 5.7% rise in FY25 revenue with underlying EBIT meeting consensus, buoyed by strong pathology growth and a significant profit from the Lumus Imaging sale. Despite challenges at Agilex Biolabs and a major goodwill impairment, the company targets improved margins by 2027.

Orbital Corporation reveals a strategic pivot amid evolving US drone policies, with a new management team driving growth beyond Boeing Insitu. FY25 guidance shows revenue decline but promising new contracts.